Rumors at the last ENC became true....
On 10/14/2014 12:56 PM, Hirschinger, Jerry D wrote:
> JEOL is still in the business. See:
> http://www.j-resonance.com/en/
>
>
>
> -----Original Message-----
> From: Helene Citeau [mailto:heleneciteau_at_sandiego.edu]
> Sent: Tuesday, October 14, 2014 1:54 PM
> To: Pierre Audet; ammrl_at_ammrl.org
> Subject: Re: AMMRL: Agilent Technologies to Close Nuclear Magnetic Resonance Business
>
> That only leaves Bruker as an NMR manufacturer, right?
>
> Best regards,
>
>
> Hélène
>
>
>
> Dr. Hélène Citeau
> Director of Scientific Instruments
> Department of Chemistry and Biochemistry Donald P. Shiley Center for Science and Technology University of San Diego
> 5998 Alcalà Park
> San Diego, CA 92110
> Ph.619 260 2920
> Fx 619 260 2211
>
>
>
> On 10/14/14 10:34 AM, "Pierre Audet" <Pierre.Audet_at_chm.ulaval.ca> wrote:
>
>> Is that true ? See below !
>>
>> ------
>> Pierre Audet, Chimiste
>> Spécialiste résonance magnétique et spectrométrie de masse Département
>> de chimie Pavillon Alexandre-Vachon
>> 1045 Avenue de la Médecine
>> Université Laval (Québec)
>> CANADA G1V 0A6
>> Tél: (418) 656-2131 x4296
>> Fax: (418) 656-7916
>> Skype: pierre.m.audet
>>
>>
>> http://www.agilent.com/about/newsroom/presrel/2014/14oct-gp14028.html
>>
>> Agilent Technologies to Close Nuclear Magnetic Resonance Business
>>
>> SANTA CLARA, Calif., Oct. 14, 2014
>>
>> Agilent Technologies Inc. (NYSE: A) today announced it is exiting its
>> Nuclear Magnetic Resonance business. Agilent entered the NMR business
>> in 2010, with the acquisition of Varian. Since then, the business has
>> not met growth and profitability objectives.
>>
>> "Today's announcement represents a difficult decision necessary to
>> drive improved profitability," said Mike McMullen, president and chief
>> operating officer, and CEO-elect. "The NMR team has been extremely
>> dedicated and has made many excellent contributions. However, this
>> action is a step in ensuring that our investments are placed on
>> higher-value life sciences, applied markets and diagnostics solutions
>> that will continue to drive growth across the company."
>>
>> Agilent will stop taking new NMR system orders immediately, but the
>> company will continue to meet customer commitments for orders in
>> progress and for ongoing support contracts. Agilent will continue to
>> provide service on all installed NMR systems.
>>
>> The company expects that this decision will eliminate about 300 jobs,
>> mostly within the next 12 months. The majority of the affected
>> positions are located in Yarnton, U.K., and Santa Clara, California.
>>
>> Today's announcement is part of Agilent's strategy to address the
>> business shortfalls of its Research Products Division. In early 2013
>> Agilent announced its exit of the OEM and Specialty Magnet business and
>> later the MRI business to focus resources on the core NMR portfolio.
>> Despite these adjustments, the NMR business has continued to fall short
>> of growth and profitability objectives.
>>
>> To cover the cost of exiting this business, Agilent will take an
>> approximate $72 million restructuring charge in the fourth quarter. It
>> expects a $20 million to $30 million decline in revenues in fiscal year
>> 2015 due to the NMR business closure, but a positive impact of about
>> $10 million in operating profit in FY15.
>>
>> For the fourth quarter of 2014, Agilent anticipates non-GAAP earnings
>> per share of $0.87 to $0.91, and projects revenues to be negatively
>> affected by currency at about $13 million, and lower NMR-related
>> revenues by about
>> $12 million.
>>
>> Keysight has posted its investor roadshow slide deck on its website at
>> www.investor.keysight.com. "New Agilent" will post its investor
>> roadshow slide deck on Friday, Oct. 17, after the market closes at
>> www.investor.agilent.com.
>>
>> About NMR
>>
>> Nuclear magnetic resonance (NMR) spectroscopy is an analytical
>> chemistry technique used in quality control and research for
>> determining the content and purity of a sample as well as its molecular
>> structure. It is used primarily in academia and government, the
>> pharmaceutical, biotech and chemical industries.
>>
>> About Agilent Technologies
>> Agilent Technologies Inc. (NYSE: A) is the world's premier measurement
>> company and a technology leader in chemical analysis, life sciences,
>> diagnostics, electronics and communications. The company's 20,600
>> employees serve customers in more than 100 countries. Agilent had
>> revenues of $6.8 billion in fiscal 2013. Information about Agilent is
>> available at www.agilent.com.
>>
>> On Sept. 19, 2013, Agilent announced plans to separate into two
>> publicly traded companies through a tax-free spinoff of its electronic
>> measurement business. The new company is named Keysight Technologies,
>> Inc. The separation is expected to be completed in early November 2014.
>>
>> Forward-Looking Statements
>>
>> This news release contains forward-looking statements as defined in the
>> Securities Exchange Act of 1934 and is subject to the safe harbors
>> created therein. The forward-looking statements contained herein
>> include, but are not limited to, information regarding the separation
>> of Agilent's electronic measurement business; future revenues, earnings
>> and profitability; the future demand for the company's products and
>> services; and customer expectations. These forward-looking statements
>> involve risks and uncertainties that could cause Agilent's results to
>> differ materially from management's current expectations. Such risks
>> and uncertainties include, but are not limited to, unforeseen changes
>> in the strength of our customers' businesses; unforeseen changes in the
>> demand for current and new products, technologies, and services;
>> customer purchasing decisions and timing, and the risk that we are not
>> able to realize the savings expected from integration and restructuring activities.
>>
>> In addition, other risks that Agilent faces include those detailed in
>> Agilent's filings with the Securities and Exchange Commission,
>> including our latest Form 10-K and Form 10-Q. Forward-looking
>> statements are based on the beliefs and assumptions of Agilent's
>> management and on currently available information. Agilent undertakes
>> no responsibility to publicly update or revise any forward-looking statement.
>>
>> # # #
>>
>> Contact:
>>
>> Michele Drake
>> +1 408 345 8396
>> michele_drake_at_agilent.com
>>
>> Neil Rees (U.K.)
>> +44 186 529 1472
>> neil_rees_at_agilent.com
>>
>> Investor Contact:
>>
>> Alicia Rodriguez
>> +1 408 345 8948
>> alicia_rodriguez_at_agilent.com
>>
> .
>
Received on Tue Oct 14 2014 - 11:32:39 MST